October 20, 2005Open Access

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer. (ClinicalTrials.gov number, NCT00045032.)

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Martine Piccart

Marion Procter

Brian Leyland‐Jones

Journals

New England Journal of Medicine

Actions

Institutions

Dana-Farber Cancer Institute

McGill University

Ludwig-Maximilians-Universität München

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Puntos clave

Resumen

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study